Bristol-Myers Squibb Company (BMY) $64.72
Bristol-Myers Squibb is riding a 16.5% three-month heater, but the stock is now slamming into a technical ceiling that has historically capped gains.
52-wk High $68.1
📌 Investment Snapshot
- Trading at 14.3x P/E with a robust 3.89% dividend yield.
- Q2 2026 revenue of $12.97B and EPS of $1.62 beat expectations.
- Recent Argus Research upgrade to Buy provides fundamental tailwinds.
- Consensus target of $66.21 offers limited 2.3% immediate upside.
⏳ WAIT
BMY has surged 12.5% in 30 days, pushing the RSI into overbought territory while approaching the $68.10 annual high. The stock needs a cooling period to validate recent gains before a fresh entry is warranted.
| 📍 Entry Zone | $60.50 or below | 🛑 Stop-Loss | $57.80 |
| 📋 Adjust If | RSI drops below 45 while holding the SMA50. | ||
The Investment Case — Why Now?
The narrative around Bristol-Myers has shifted from patent-cliff anxiety to a story of successful pipeline execution over the last 90 days. Revenue jumped from $11.49B in Q1 to $12.97B in Q2, signaling that new product launches are finally offsetting legacy Eliquis and Opdivo pressures. Institutional confidence is returning, evidenced by the 16.5% quarterly return and a flurry of maintained ‘Buy’ ratings from Guggenheim and Truist.
Despite the fundamental progress, the primary risk remains the thin margin of safety at current price levels. With the stock trading just 5% below its 52-week high, any clinical trial setback or regulatory headwind could trigger a sharp mean reversion. Can the current portfolio growth sustain a breakout above $70 without a significant new catalyst before October earnings?
The technical confluence score of 60/100 reflects a stock that is fundamentally sound but technically overextended. While the ADX at 65.1 confirms a powerful trend, the RSI at 71.9 warns that the ‘easy money’ in this leg of the rally has been made.
🤔 Can the current portfolio growth sustain a breakout above $70 without a significant new catalyst before October earnings?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers – General |
| Dividend Yield | 3.89% |
| Next Earnings | Oct 29, 2026 |
Open chart on TradingView →
📈 Price Action & Technicals
Golden Cross
Outside VA
Sell-side Sweep at $58.49 on 2026-07-13
BMY is currently trading well above its SMA50 ($58.44) and SMA200 ($55.11), confirming a powerful long-term bullish trend. However, the distance from these moving averages suggests the stock is ‘stretched’ and prone to a short-term pullback.
The RSI at 71.9 screams overbought, a level that has historically preceded consolidation periods for this ticker. While the MACD remains in a bullish golden cross, the narrowing gap between the MACD and signal line suggests momentum is beginning to plateau.
Price action has moved outside the Volume Profile Value Area ($52.54–$60.32), indicating that BMY is currently in a price discovery phase. The Point of Control at $56.92 remains the ultimate magnet if a broader market correction occurs.
The ADX at 65.1 reveals an exceptionally strong trend, but such high readings often coincide with trend exhaustion. Bollinger Bands show the stock hugging the upper band ($67.22), which typically acts as a dynamic resistance zone.
Three recent sell-side liquidity sweeps near $58 suggest that institutional ‘smart money’ was active at lower levels. We expect the stock to seek the unfilled Bullish FVG at $59.19~$60.47 before attempting a sustained move toward $70.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| BMY | Bristol-Myers Squibb | 14.3x |
| PFE | Pfizer Inc. | 12.1x |
| MRK | Merck & Co. | 16.8x |
| LLY | Eli Lilly | 48.5x |
| SPY | S&P 500 Avg | 21.4x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 2026 | $12.97B | $1.62 | +12.8% |
| Q1 2026 | $11.49B | $1.31 | +8.2% |
| Q4 2025 | $12.50B | $0.53 | -4.1% |
| Q3 2025 | $12.22B | $1.08 | +2.3% |
BMY generated a healthy $3.1B in Free Cash Flow in the latest quarter, comfortably covering its $1.3B dividend obligation.
The Q2 2026 results marked a significant turning point, with revenue growth accelerating to double digits. This performance validates management’s strategy of diversifying the oncology and immunology portfolios to mitigate upcoming patent expirations.
🚀 Growth Drivers — What Moves the Stock
- New Product Portfolio 🟢 Upside Surprise — Growth in Reblozyl and Opdualag is successfully offsetting the decline in Revlimid sales.
- KarXT Launch 🟢 Upside Surprise — The upcoming commercialization of KarXT in schizophrenia represents a multi-billion dollar opportunity.
- M&A Integration 🟡 Priced In — Successful integration of Karuna and RayzeBio acquisitions is beginning to show in the pipeline efficiency.
🤔 Will the KarXT launch be enough to propel BMY past its historical valuation ceiling of 16x forward earnings?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 171,682 |
| Vanguard Capital Management LLC | 132,320 |
| State Street Corporation | 98,564 |
| JPMORGAN CHASE & CO | 92,475 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| MASSACESI CRISTIAN | Officer | 2026-07-31 | Purchase | 51172 |
| ELKINS DAVID VINCENT | CFO | 2026-04-01 | Purchase | 30000 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 2.2% | 3.3 |
⚠ Key Risk Factors
~$2.5B impact
~$10B market cap
🎯 Guidance & Wall Street View
Management has raised full-year 2026 revenue guidance, citing strong demand for newly launched therapies and improved operational efficiency.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $80.00 | $66.21 | $40.00 | 24 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Argus Research | Buy | $75.00 | 2026-08-05 | Upgrade |
| JP Morgan | Overweight | $70.00 | 2026-07-31 | Maintained |
| Citigroup | Neutral | $62.00 | 2026-08-03 | Maintained |
While the consensus remains a ‘Buy’, the mean target of $66.21 is nearly identical to the current price, suggesting analysts are waiting for further data before raising targets.
Open chart on TradingView →
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- KarXT launch exceeds high-end estimates, driving a re-rating to 18x P/E.
- Dividend increases attract yield-starved investors as Fed cuts rates.
📊 Base Case
Steady pipeline execution offsets patent losses; stock trades in line with sector growth.
🐻 Bear Case
- Medicare price cuts are more aggressive than modeled, hitting top-line growth.
- Technical double-top at $68 leads to a retracement to the SMA200 at $55.
🎯 Investor Action Plan — By Profile
Avoid chasing at the upper Bollinger Band. Wait for a pullback to the $60.47 FVG zone to manage risk-reward effectively.
Maintain current positions to collect the 3.89% yield, but defer adding new capital until the RSI cools below 50.
The valuation is attractive at 14x, but better entry points typically emerge after such vertical 16% moves.
If you’re interested in the Healthcare sector, also read:
❓ Investor FAQ — People Also Ask
Q: Is BMY's dividend safe?
Yes, with a $3.1B quarterly free cash flow and a payout ratio that remains manageable, the 3.89% yield is well-covered.
Q: What is the next major catalyst for BMY?
The Q3 earnings report on October 29, 2026, and further updates on the KarXT commercial rollout are the key events to watch.
Q: Why is the Technical Confluence Score only 60?
While the trend is strong (ADX), the stock is overextended relative to its Volume Profile Point of Control and VWAP, suggesting a lack of immediate support.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 Want to check the current price action yourself?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Pharmaceutical stocks carry unique risks related to clinical trials and regulation.
All active positions and their real-time performance are tracked on our Investment Log.
#BMY #BristolMyers #PharmaStocks #Dividends #StockMarket #Investing #TechnicalAnalysis